Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $75.81 USD
Change Today +0.60 / 0.80%
Volume 1.2M
DGX On Other Exchanges
Symbol
Exchange
New York
Stuttgart
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

quest diagnostics inc (DGX) Snapshot

Open
$75.59
Previous Close
$75.21
Day High
$75.99
Day Low
$74.76
52 Week High
03/24/15 - $78.33
52 Week Low
04/28/14 - $54.90
Market Cap
10.9B
Average Volume 10 Days
1.7M
EPS TTM
$4.23
Shares Outstanding
143.8M
EX-Date
04/6/15
P/E TM
17.9x
Dividend
$1.52
Dividend Yield
1.81%
Current Stock Chart for QUEST DIAGNOSTICS INC (DGX)

quest diagnostics inc (DGX) Related Businessweek News

View More BusinessWeek News

quest diagnostics inc (DGX) Details

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry. It also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV serology; and DxSelect IFA and ELISA products for testing infectious diseases. In addition, the company offers molecular diagnostic products in various segments, such as HIV-1 drug resistance testing under the ViroSeq brand name; and reproductive genetics and transplantation under the Atria and AlleleSeqr brand names. Further, it provides Care360 EHR, a solution that allows doctors to electronically create, manage, and distribute patient encounter notes, as well as for patient communication through a patient portal; and ChartMaxx, an enterprise content management system for hospitals. The company primarily offers its diagnostic information services under the Quest Diagnostics, AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Solstas, and Summit Health brands to patients, physicians, hospitals, accountable care organizations, integrated delivery networks, health plans, employers, and other customers through a network of laboratories, patient service centers, and phlebotomists in physician offices. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

45,000 Employees
Last Reported Date: 04/23/15
Founded in 1967

quest diagnostics inc (DGX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $550.0K
Senior Vice President of Operations
Total Annual Compensation: $536.5K
Chief Medical Officer, Senior Vice President ...
Total Annual Compensation: $573.9K
Senior Vice President and Group Executive of ...
Total Annual Compensation: $534.6K
Compensation as of Fiscal Year 2014.

quest diagnostics inc (DGX) Key Developments

Quest Diagnostics Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Year 2015

Quest Diagnostics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company's net revenues were $1,839 million compared to $1,746 million a year ago. Operating income was $228 million compared to $208 million a year ago. Income before income taxes was $112 million compared to $176 million a year ago. Net income was $70 million compared to $111 million a year ago. Reported net income in the first quarter of 2015 was negatively impacted by charges of $80 million after tax, or $0.54 per diluted share, principally associated with the early retirement of debt in connection with the company's recent debt refinancing. In addition, a portion of the charges were related to restructuring and integration costs and ongoing efforts to drive operational excellence. Net income attributable to Quest Diagnostics was $61 million compared to $104 million a year ago. Earnings per share attributable to Quest Diagnostics' common stockholders- diluted was $0.42 compared to $0.71 a year ago. Net cash provided by operating activities was $52 million compared to $84 million a year ago. Capital expenditures were $56 million compared to $68 million a year ago. Earnings available to Quest Diagnostics' common stockholders - basic and diluted was $61 million compared to $103 million a year ago. Adjusted operating income was $269 million compared to $236 million a year ago. Adjusted net income was $141 million compared to $122 million a year ago. Adjusted diluted EPS excluding amortization expense was $1.05 compared to $0.93 a year ago. Adjusted cash provided by operations was $130 million compared to $84 million a year ago. For 2015, the company estimates results from continuing operations, before special items, as follows: Revenues to increase 2% to 3% compared to 2014; diluted EPS to be between $3.83 and $3.98; Adjusted diluted EPS excluding amortization to be between $4.70 and $4.85; cash provided by operations to approximate $772 million; Adjusted cash provided by operations to approximate $850 million; and Capital expenditures to approximate $300 million.

Quest Diagnostics Incorporated Unveils Series of New Population Health, Data Analytics and Decision Support Solutions

Quest Diagnostics Incorporated has unveiled a series of new population health, data analytics and decision support solutions. The new solutions, featuring Interactive Insights by Care360 reports and IntelliTest Analytics, are designed to promote clinically appropriate test selection and tracking of quality and care metrics, among other benefits, to enhance patient care and outcomes for both the individual patient and large managed populations. Interactive Insights by Care360 is a web-based reporting solution for physicians and patients that provides health insights based on a patient's lab data to improve decision making by both the physician and patient. The solution provides lab test results in a graphically rich and interactive format with clinical content, such as related medical guidelines, educational materials and clinical test algorithms, pertinent to the individual patient. With these resources available in a single platform, the physician may be more likely to select appropriate test services guided by a holistic understanding of the patient's individual medical needs. Interactive Insights also provides a simplified graphical view and patient educational materials to help the clinician have a dialogue with the patient to promote engagement in medical decisions. Interactive Insights is available via MyQuest patient portal and Care360 connectivity solutions as well as through designated qualified EHR vendors.

Quest Diagnostics Inc. Unveils Suite of New Technology Solutions

Quest Diagnostics will unveil a suite of new technology solutions during the HIMSS 2015 Annual Conference & Exhibition. The new solutions, featuring Interactive Insights by Care360 reports and IntelliTest Analytics, are designed to promote clinically appropriate test selection and tracking of quality and care metrics, among other benefits, to enhance patient care and outcomes for both the individual patient and large managed populations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $75.81 USD +0.60

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMerieux €98.06 EUR +0.84
Hologic Inc $33.99 USD +0.56
Laboratory Corp of America Holdings $126.93 USD +0.55
QIAGEN NV €22.90 EUR +0.004
Roper Industries Inc $169.92 USD -0.13
View Industry Companies
 

Industry Analysis

DGX

Industry Average

Valuation DGX Industry Range
Price/Earnings 21.7x
Price/Sales 1.5x
Price/Book 2.6x
Price/Cash Flow 18.1x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.